Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor

Cancer Research

Volumn 69, Issue 12, 2009, Pages 5151-5158

  Kamiryo, Yoriyuki ^a,b   Eto, Masatoshi ^b   Yamada, Hisakata ^a   Yajima, Toshiki ^a,c   Harano, Masahiko ^b   Takeuchi, Ario ^a,b   Tatsugami, Katsunori ^b   Hamaguchi, Masumitsu ^b   Naito, Seiji ^b   Yoshikai, Yasunobu ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; BONE MARROW CELL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DONOR LYMPHOCYTE INFUSION; FEMALE; MOUSE; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SERODIAGNOSIS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; STEM CELL TRANSPLANTATION;

EID: 67449128459     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2517     Document Type: Article

References (42)

1. Childs R, Chernoff A, Contentin N. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758 (Pubitemid 30691373)
2. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002;20:2017-2024 (Pubitemid 34408790)
3. Barkholt L, Bregni M, Remberger M, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006;17:1134-1140 (Pubitemid 43985250)
4. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002;99:4234-4236 (Pubitemid 35332074)
5. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998;16:986-993 (Pubitemid 28108731)
6. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004;22:3886-3892 (Pubitemid 41079869)
7. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003;103:790-795
8. Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005;366:318-320 (Pubitemid 41019423)
9. Hentschke P, Barkholt L, Uzunel M, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003;31:253-261 (Pubitemid 36336227)
10. Bay JO, Fleury J, Choufi B, et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 2002;30:95-102. (Pubitemid 34906092)
11. Pedrazzoli P, Da Prada GA, Giorgiani G, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002;94:2409-2415 (Pubitemid 34457122)
12. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465
13. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562 (Pubitemid 20069191)
14. Truitt RL, Johnson BD. Principles of graft-vs.-leukemia reactivity. Biol Blood Marrow Transplant 1995;1:61-68
15. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-1023
16. Teshima T, Liu C, Lowler KP, Dranoff G, Ferrara JL. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res 2002;62:796-800. (Pubitemid 34126956)
17. Slavin S, Seidel H. Hemopoietic activity in bone marrow chimeras prepared with total lymphoid irradiation (TLI). Exp Hematol 1982;10:206-216 (Pubitemid 12178908)
18. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus- host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991;77:2515-2523
19. Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 1995;23:196-201.
20. + T cells in cyclophosphamide- induced tolerance to H-2-compatible, Mls-disparate antigens. J Exp Med 1990;171:97-113.
21. Eto M, Mayumi H, Tomita Y, et al. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol 1991;146:1402-1409
22. Harano M, Eto M, Iwai T, et al. Renal cancer treatment with low level of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice. Cancer Res 2005;65:10032-10040 (Pubitemid 41541485)
23. Tomonari K, Fairchild S, Rosenwasser OA. Influence of viral superantigen on Vβ- and Vα-specific positive and negative selection. Immunol Rev 1993;131:131-168 (Pubitemid 23101140)
24. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The role of minor H antigens and endotoxin. Blood 1996;8:3230-3239
25. Maeda T, Eto M, Nishimura Y, Nomoto K, Kong YY, Nomoto K. Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice. J Immunol 1993;150:753-762 (Pubitemid 23133655)
26. Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning; critical role for recipient-derived IFN-γ. Blood 2003;102:2300-2307 (Pubitemid 37122413)
27. + T cells. J Immunol 2005;175:665-676
28. Heath WR, Carbone FR. Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol 1999;11:314-318 (Pubitemid 29263960)
29. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
30. Eto M, Harada M, Tamada K, et al. Antitumor activity of interleukin-12 against murine bladder cancer. J Urology 2000;163:1549-1552 (Pubitemid 30226325)
31. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368
32. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci U S A 1994;91:9407-9411 (Pubitemid 24297923)
33. Chakraverty R, Eom HS, Sachs J, et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusion. Blood 2006;108:2106-2113 (Pubitemid 44395027)
34. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002;100:1903-1909 (Pubitemid 34925172)
35. + T cell-mediated graft-versus- tumor effect that is independent of the recognition of alloantigenic tumor targets. Blood 2004;104:1210-1216
36. Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, Perreault C. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 2005;11:1222-1229 (Pubitemid 43093670)
37. Fontaine P, Proulx GR, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001;7:789-794 (Pubitemid 32691632)
38. Dey BR, McAfee S, Colby C, et al. Anti-tumor response despite loss of donor chimerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005;128:351-359 (Pubitemid 40216157)
39. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-3241 (Pubitemid 29512733)
40. Eto M, Harano M, Tatsugami K, et al. Cyclophosphamide-using nonmyeloablative allogeneic cell therapy against renal cancer with a reduced risk of graft-versus-host disease. Clin Cancer Res 2007;13:1029-1035 (Pubitemid 46340382)
41. Eto M, Kamiryo Y, Takeuchi A, et al. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Clin Cancer Res 2008;14:2833-2840
42. Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 2008;118:1099-1109